284 related articles for article (PubMed ID: 24684240)
1. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
2. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
Adell A
IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine: first global approval.
Gibb A; Deeks ED
Drugs; 2014 Jan; 74(1):135-45. PubMed ID: 24311349
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine: a review of its use in major depressive disorder.
Garnock-Jones KP
CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
9. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine hydrobromide, crofelemer, and teduglutide.
Hussar DA; Lye A
J Am Pharm Assoc (2003); 2014; 54(1):91-4. PubMed ID: 24407747
[No Abstract] [Full Text] [Related]
14. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
Al-Sukhni M; Maruschak NA; McIntyre RS
Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
16. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
19. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
20. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
